Board of Directors
Lota S. Zoth, CPA (Chair)
Former Senior VP and CFO of MedImmune, Inc.
Lota Zoth is a strategic finance and operations expert who served as Senior Vice President and Chief Financial Officer of MedImmune, Inc., a biopharmaceutical company based in Gaithersburg, Maryland. Ms Zoth contributes extensive financial and operational experience from her tenure as CFO at MedImmune and her previous senior corporate financial, accounting and management positions. In addition to her role as Senior Vice President and Chief Financial Officer at MedImmune from 2002 to 2007, she has also held senior financial and accounting roles at PSINet, Sodexho Marriott Services, Inc., Marriott International, Inc., PepsiCo, Inc. and Ernst & Young, the global accounting and consulting firm. She currently serves as audit committee chair on the governing boards of four biopharmaceutical companies, Hyperion Therapeutics, NewLink Genetics, Orexigen Therapeutics and Ikaria. Ms. Zoth is a certified public accountant.
Barry Bloom, PhD
Distinguished Service Professor at Harvard University
Barry Bloom has been a pioneer in infectious disease research and vaccine science. He served as dean of the Harvard School of Public Health from 1999 to 2009 and spent over 35 years as principal investigator researching the immune response to TB in his Harvard lab. Prior to his work at Harvard, Dr. Bloom served as chairman of the Department of Microbiology and Immunology at the Albert Einstein College of Medicine and as an investigator at the Howard Hughes Medical Institute. Dr. Bloom earned his BS from Amherst College and PhD from Rockefeller University. He is the recipient of multiple prestigious awards, including the first Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Diseases Research, a shared Novartis Prize for Clinical Immunology and the Robert Koch Gold Medal for lifetime research in infectious diseases. He is a member of the National Academy of Sciences, the Institute of Medicine, the American Association for the Advancement of Science, and the American Philosophical Society. He currently serves on over 15 boards and advisory committees, including the Board of Trustees for the Tuberculosis Vaccine Initiative (TBVI), and as Chairman Emeritus of the International Vaccine Institute (IVI).
David L. Blumberg
Former Life Sciences Sector Leader of KPMG
David L. Blumberg has more than 20 years of business and consulting experience across the life sciences continuum, including global, specialty, and generic pharmaceuticals, biotech, and medical devices and products. Mr. Blumberg recently retired from KPMG where he led their U.S. Pharmaceuticals and Life Sciences Advisory practice. Previously, he was the Executive Vice President of Professional Services and Customer Support of a public software company that specializes in contract and demand management for life sciences corporations. He spent several years at Accenture, where he served as lead partner for the Pharmaceutical and Medical Products Industries and led one of the corporation’s largest account relationships. Mr. Blumberg has an M.B.A. from The Wharton School and a B.S. degree in mechanical engineering from Ohio State University. He is a guest lecturer at The Wharton School, the Harvard Business School and at the New York Institute of Technology. Mr. Blumberg also serves on the Board of Advisors for the Vagelos Life Sciences and Management Program at The Wharton School and the University of Pennsylvania.
Former President & CEO of Aeras
Jim Connolly is the former President and CEO of Aeras. He joined Aeras after more than two decades of pharmaceutical industry experience. As Executive Vice President and General Manager of Wyeth Vaccines from 2005 to 2009, he played a leading role in expanding access to the breakthrough pneumococcal vaccine Prevnar to more than 100 countries and 35 national immunization programs, including numerous emerging and developing countries where pneumococcal disease is a major cause of child mortality. In the course of his career at Wyeth, Mr. Connolly held a number of increasingly senior management, commercial and finance positions, including President and Managing Director of Wyeth Canada; Area Business Director for California and Nevada; Business Director of Wyeth’s disease management joint venture with Merck-Medco; and Director of Finance for Wyeth Pharmaceuticals. He is a graduate of Washington University in St. Louis, Missouri, with a degree in Business Administration.
Marja Esveld, MSc
Senior Advisor, Research and Innovation, Ministry of Health (The Netherlands)
Marja Esveld is an infectious diseases epidemiologist by training and currently holds the position of Senior Advisor for International Innovation and Research at the Ministry of Health in the Netherlands. In her current job she is, among others, Member of the Health Committee for the 7th EU Research Framework and the Advisory Committee of the EU Public Health Programme. In these positions she is the link between the Dutch Topsector Policy for Life Sciences and Health and international policy. She is vice-chair of the European Developing Countries Clinical Trials Partnership (EDCTP), and also represents the Netherlands on the WHO Expert Working Group on Global Health Research and Financing (CEWG). Recently she was appointed as Government Representative on the Expert Review Committee of the Access to Medicines Index 2014.
Ms. Esveld was seconded for four years to the Dutch Ministry of Foreign Affairs, were her main areas of work were global TB control and biomedical research for poverty related diseases. As part of her work, she managed grants with Product Development Partnerships (PDPs) in the areas of AIDS, TB and other neglected diseases. She also represented The Netherlands and Sweden on the Board of the UN Special Programme for Tropical Diseases Research (TDR) and represented the Netherlands and UK on the StopTB Partnership Board. For the last two years she represented the Netherlands in the constituency of the Global Fund for AIDS, TB and Malaria.
Earlier positions were with the National Institute of Public Health (RIVM), the Ministry of Health, the World Health Organization (Geneva) and the Inspectorate for Health Care.
Marian Eslie Jacobs
Professor Marian Eslie Jacobs is based in Cape Town, South Africa, where she was Dean and Emeritus Professor of Paediatrics and Child Health Faculty of Sciences at the University of Cape Town. She is currently retired and serves as the Chair of the Ministerial Advisory Committee, Academy for Leadership and Management in Healthcare, and the National Department of Health. She is also a member of the Gulbenkian Foundation Global Mental Health Initiative Advisory Committee, Doris Duke Africa Health Initiative Advisory Board, and the World Health Organization (WHO) Maternal, Child and Adolescent Health Technical Reference Group. Professor Jacobs has her M.B. and Ch.B. from the University of Cape Town and has authored numerous publications in peer-reviewed journals, as well as books, chapters, proceedings and technical reports in the fields of paediatrics, child health, child policy, public health and health systems (including global health).
Professor Michel Kazatchkine, M.D.
Senior Fellow, Global Health Programme, Graduate Institute of International and Development Studies
Professor Michel Kazatchkine has spent the last 30 years fighting AIDS as a leading physician, researcher, administrator, advocate, policymaker, and diplomat. He attended medical school at Necker-Enfants-Malades in Paris, studied immunology at the Pasteur Institute and completed postdoctoral fellowships at St Mary’s Hospital in London and Harvard Medical School. Professor Kazatchkine has played key roles in various organizations, including serving as Director of the National Agency for Research on AIDS (ANRS) in France (1998-2005) and Chair of the WHO’s Strategic and Technical Committee on HIV/AIDS (2004-2007). From 2005 to 2007, Professor Kazatchkine served as French Ambassador for the fight against HIV/AIDS and Communicable Diseases.
In 2007, he was elected Executive Director of the Global Fund, a position in which he served until March 2012. In July 2012, Professor Kazatchkine was appointed as the UN Secretary-General’s Special Envoy on HIV/AIDS in Eastern Europe and Central Asia.
Wayne F. Pisano
President and CEO, VaxInnate
Wayne Pisano is the President and CEO of VaxInnate, a privately held biotech company whose recombinant protein technology is being developed to produce highly immunogenic vaccines that can be manufactured at low cost. He is the former President and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. Mr. Pisano retired from Sanofi Pasteur in February 2011 after 14 years with the global vaccines company, during which he played a leading role in its overall growth and success. During his career at Sanofi Pasteur, he held several increasingly senior leadership positions in global commercial operations and sales and marketing. He also played a key role in the organization’s strategic research and development efforts to advance the company’s portfolio of vaccines against diseases in both the developed and developing world. Mr Pisano also previously served as a Vice President at Novartis Pharmaceuticals Corp. In 2010, he was named Pharma Executive of the Year at the World Vaccine Congress.
Regina Rabinovich, MD, MPH
Exxon Mobil Malaria Scholar in Residence, Harvard School of Public Health
Regina Rabinovich is the ExxonMobil Malaria Scholar in Residence at Harvard University. She has over 25 years of experience in global health across research, public health, and philanthropic sectors, with focus on strategy, global health product development, and the introduction and scale-up of tools and strategies resulting in impact on endemic populations. From 2003-2012, Dr. Rabinovich served as Director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment, and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea, and neglected infectious diseases. Dr. Rabinovich has served in Chief of the Clinical and Regulatory Affairs Branch at the US National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of US clinical research units. She participated in the Children’s Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world. In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the boards of AERAS, a non-profit biotech focused on development of vaccines for tuberculosis, and the Catholic Medical Mission Board.
Dr. Rabinovich holds a medical degree from Southern Illinois University and a Masters of Public Health degree from the University of North Carolina.
Gerd Zettlmeissl, PhD
Former CEO of Intercell AG
Gerd Zettlmeissl is the former CEO of the Austrian-based biotechnology company Intercell AG, and is an accomplished vaccine expert and biopharmaceutical business executive. Dr. Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. While at Intercell AG from 2001 to 2011, he built the company from a private start up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl held senior management roles at Chiron Corp and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress.